Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
affect decrease » effects decreased (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
affect decrease » effects decreased (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
-
4121
a) Number weighted mean volume of AEII during postnatal development and in adults. There are no volume alterations before and at the end of bulk alveolarization. A significant increase was determined in adults compared to 3 and 7 days old pups. b) Size of AEII presented as V<sub>S</sub>-ratioAEII during postnatal lung development into adulthood. Before and during bulk alveolarization there are no size changes. Adults show a significant increase compared to values before and at onset of alveolarization. c) Number weighted mean volume of AEII per lung volume during postnatal development and in adults. The highest values are seen before alveolarization. During alveolarization the quotient decreases and reaches significance compared to 3 days old pups at postnatal day 21....
Published 2025“…During alveolarization the quotient decreases and reaches significance compared to 3 days old pups at postnatal day 21. …”
-
4122
-
4123
Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3.
Published 2024Subjects: -
4124
-
4125
-
4126
Line graph showing the values of inflammatory cytokines at baseline and after treatment.
Published 2025Subjects: -
4127
Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness.
Published 2024Subjects: -
4128
-
4129
-
4130
-
4131
Frequency distribution of SOLEC at baseline and follow-ups in the NSEIT and NSE groups.
Published 2024Subjects: -
4132
-
4133
Baseline and Post-Treatment Results of Echocardiographic Variables in Each Experimental Group.
Published 2025Subjects: -
4134
-
4135
-
4136
Baseline descriptive characteristics of trial participants with dizziness, by treatment group.
Published 2024Subjects: -
4137
-
4138
Baseline and Post-Treatment Serum Cytokine Levels in Each Investigational Group.
Published 2025Subjects: -
4139
-
4140
Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group.
Published 2025Subjects: